Peptides DB
Research-centric peptide and protocol reference hub
Study 47 of 48Vasopressin literaturebiorxiv-preprint · Observational · Preclinical2026

Allelic heterogeneity and cystic pathway modulation in HNF1B disease

The study highlights the complex relationship between HNF1B variants and their phenotypic outcomes, suggesting potential pharmacological avenues for managing cystic burden in related conditions.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the vasopressin corpus
9
Preclinical
35
Observational · this one
1
Open-label
2
Randomised
1
Reviews

Summary and findings

This study investigates the relationship between HNF1B variants and their associated phenotypes, particularly focusing on renal cysts and diabetes. The research also evaluates the pharmacological modulation of cystogenesis in a kidney-specific Hnf1b knockout mouse model. Not reported in abstract.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> Heterozygous <italic>HNF1B</italic> variants cause a clinically heterogeneous disorder ranging from isolated renal anomalies to renal cysts and diabetes (RCAD) syndrome. To define allele-level genotype–phenotype relationships, we curated 329 pathogenic or likely pathogenic intragenic <italic>HNF1B</italic> variants from ClinVar and HGMD and annotated reported RCAD, kidney-only and diabetes-only phenotypes. Predicted loss-of-function (pLOF) variants were more frequently associated with RCAD, whereas missense variants were enriched for diabetes-only presentations. Missense variants showed substantial phenotypic overlap without clear domain-specific segregation. Higher AlphaMissense scores were observed among RCAD-associated missense variants, although DNA-binding-domain localization showed the stronger association with RCAD. To test whether cystogenesis resulting from <italic>Hnf1b</italic> loss remains pharmacologically modifiable, we evaluated selected cystogenic pathways and glutamatergic signaling in a kidney-specific <italic>Hnf1b</italic> knockout mouse model. CFTR inhibition, vasopressin receptor antagonism and systemic AMPK activation reduced cystic burden, whereas NMDA receptor modulation showed no significant effect. These findings support partial variant-class-associated phenotypic effects in <italic>HNF1B</italic> disease while highlighting extensive allele-level pleiotropy, and provide <italic>in vivo</italic> proof-of-concept that selected downstream cystogenic pathways remain pharmacologically modifiable despite <italic>Hnf1b</italic> loss. </p>

Background

This paper addresses the clinical heterogeneity associated with heterozygous HNF1B variants, which can lead to various renal and metabolic disorders. Previous studies have identified a range of phenotypes linked to HNF1B mutations, but the specific genotype-phenotype relationships remain inadequately defined. Understanding these relationships is crucial for better diagnosis and management of HNF1B-related conditions.

Methods

The study involved curation of 329 pathogenic or likely pathogenic intragenic HNF1B variants from ClinVar and HGMD. A kidney-specific Hnf1b knockout mouse model was used to evaluate the effects of pharmacological interventions on cystogenesis. The primary outcome measures included the assessment of cystic burden following various treatments.

Results

CFTR inhibition, vasopressin receptor antagonism, and systemic AMPK activation reduced cystic burden. The study did not report specific numeric findings such as effect sizes or p-values in the abstract.

Interpretation

The findings suggest that certain pharmacological pathways may be modifiable in the context of HNF1B loss, which aligns with existing literature on cystogenesis. However, the clinical significance of the observed effects remains uncertain, particularly given the reliance on a mouse model and the absence of human data. This limits the applicability of the results to clinical practice.

Key findings

  • 329 pathogenic or likely pathogenic intragenic HNF1B variants curated from ClinVar and HGMD.
  • Predicted loss-of-function variants were more frequently associated with renal cysts and diabetes (RCAD).
  • Missense variants showed substantial phenotypic overlap without clear domain-specific segregation.
  • CFTR inhibition, vasopressin receptor antagonism, and systemic AMPK activation reduced cystic burden.
  • NMDA receptor modulation showed no significant effect.

Limitations

  • Study based on a mouse model, limiting human applicability.
  • No specific numeric findings reported in the abstract.
  • Focus on curated variant data may not encompass all phenotypic variations.

Elsewhere in the Vasopressin corpus

BRefractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.Toxicology reports · 2026 · n=1 · Lactate fell from 10.5 to 6.1 mmol/L over 55 min.HumanBCost Analysis of Vasopressin Use in Septic Shock and Predictive Performance of GOSSIS in ICU Mortalitybiorxiv-preprint · 2026 · cost ratio = 1.14, 95% CI: 1.08, 1.20HumanCAVPR2 antagonism with tolvaptan alters medullary cell responses and attenuates kidney injurybiorxiv-preprint · 2026 · Not reported in abstract.AnimalBFluid Resuscitation Volume After Early Echocardiography and Mortality in Sepsis: Target Trial Emulations With Strictly Pre-Exposure Confounder Measurement in MIMIC-IVbiorxiv-preprint · 2023 · n=7819 · HR 1.74, 95% CI 1.54–1.97; weighted risk 38.7% vs 24.8%; risk difference +13.9%, 95% CI 10.8–17.0.HumanBAcute colonic pseudo-obstruction with transient failure of oral desmopressin in adipsic arginine vasopressin deficiency.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanAEffect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.JAMA · 2026 · Mortality at 28 days was 31.8% in the lower-threshold group vs 33.0% in the higher-threshold group, P=0.62.Human